2 citations
,
May 2025 in “Archives of Dermatological Research” This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.
8 citations
,
May 2025 in “Dermatology and Therapy” This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.
21 citations
,
April 2025 in “MedComm” This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.
February 2025 in “PubMed” This study found that although the global incidence of alopecia areata has risen since 1990, age-standardized rates have slightly decreased, with significant comorbidity associations varying by region.
4 citations
,
January 2025 in “Dermatologica Sinica” This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.
December 2024 in “Journal of Clinical Medicine” This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.
23 citations
,
October 2024 in “British Journal of Dermatology” In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.
20 citations
,
October 2024 in “British Journal of Dermatology” In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.
9 citations
,
August 2024 in “British Journal of Dermatology” This study highlights that the incidence and mental health impact of alopecia areata is higher among non-White ethnic groups, emphasizing the need for targeted healthcare for those at greatest risk.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.
5 citations
,
June 2024 in “Value in Health Regional Issues” The study reported that from 2016 to 2020, the number of patients with alopecia areata in Taiwan increased, with severe cases utilizing more systemic therapies and having higher outpatient visits than mild/moderate cases.
21 citations
,
February 2024 in “JAMA Dermatology” This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.
January 2024 in “American journal of clinical dermatology” This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
October 2023 in “Dermatology practical & conceptual” This study found that pulse corticosteroids effectively induce hair regrowth in alopecia areata, with betamethasone showing higher efficacy but more side effects, and treatment success varying depending on age, onset time, and disease type.
1 citations
,
October 2023 in “Dermatology and therapy” This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.
3 citations
,
August 2023 in “Journal of the American Academy of Dermatology” This research emphasizes the importance of understanding patient experiences related to hair loss, highlighting that race, ethnicity, culture, resources, and mental health greatly affect these experiences. Effective counseling involves clear communication, validation, and shared decision-making to provide appropriate treatment, support, or camouflage options.
12 citations
,
June 2023 in “JAMA network open” In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.
20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” This review highlights the significant negative impact of alopecia areata on quality of life, mental health, and work, calling for individualized approaches and effective treatments to mitigate these effects.
29 citations
,
January 2023 in “Journal of Clinical Medicine” This review discusses psychological treatments for alopecia, finding limited but positive effects on mental health, quality of life, and possibly hair growth; however, more research is needed to establish intervention efficacy.
10 citations
,
January 2023 in “Annals of Dermatology” This study produced updated treatment guidelines for severe alopecia areata patients in Korea, highlighting the efficacy of systemic corticosteroids, oral cyclosporine, and Janus kinase inhibitors.
35 citations
,
November 2022 in “The Journal of Dermatology” This study found that the prevalence of alopecia areata in Japan increased from 2012 to 2019, with allergic diseases as common comorbidities and a need for more effective treatments, particularly for severe and pediatric cases.
11 citations
,
July 2022 in “Frontiers in immunology” This study reports that the global age-standardized incidence and disability-adjusted life-year rates of alopecia areata decreased from 1990 to 2019, with the highest increases in incidence seen in some low SDI regions and countries like Kuwait and South Sudan.
March 2022 in “Wound practice & research” This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” This review highlights current knowledge about quality of life assessment in alopecia areata, noting limited use of existing instruments and a need for further validation.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” This study suggests that intralesional triamcinolone acetonide at a concentration of 5 mg/mL may offer the best balance of effectiveness and safety for treating focal alopecia areata.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
14 citations
,
January 2015 in “Indian journal of dermatology, venereology, and leprology” This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.
109 citations
,
May 2011 in “Dermatologic Therapy” This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.
